8-K: Theravance Biopharma Reports Q1 2024 Results, YUPELRI Sales Surge 18%

Theravance Biopharma announced its first quarter 2024 financial results, highlighted by an 18% year-over-year increase in YUPELRI net sales and continued progress in its ampreloxetine clinical program.

Summary

• Theravance Biopharma reported a net loss of $11.7 million for the first quarter of 2024, compared to a $22.1 million loss in the same period of 2023.
• The company's non-GAAP net loss from operations was $4.5 million, a significant improvement from the $14.9 million loss in Q1 2023.
• YUPELRI net sales reached $55.2 million, an 18% increase compared to the first quarter of 2023, with hospital doses sold growing by 31%.
• Viatris collaboration revenue was $14.5 million, up 39% year-over-year, driven by higher YUPELRI sales and lower costs incurred by Viatris.
• Research and development expenses decreased to $9.0 million from $14.6 million in the same quarter last year.
• Selling, general, and administrative expenses also decreased to $16.7 million from $19.2 million year-over-year.
• The company's cash balance stood at $100 million as of March 31, 2024.
• Theravance Biopharma is eligible for up to $200 million in milestone payments from Royalty Pharma related to TRELEGY sales, with the next $25 million milestone triggered at approximately $2.9 billion in TRELEGY global net sales in 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong sales growth for YUPELRI and significant improvement in non-GAAP losses. The company's pipeline progress and financial stability are also encouraging. However, the company is still operating at a loss and faces risks related to clinical trials and regulatory approvals.

Positives

• YUPELRI sales are showing strong growth, with an 18% increase in net sales and a 31% increase in hospital doses sold.
• The company's collaboration revenue with Viatris is up 39%, indicating a strong partnership and improved profitability.
• Operating expenses, including R&D and SG&A, have decreased year-over-year, showing improved cost management.
• The non-GAAP net loss from operations has significantly improved, suggesting a move towards profitability.
• The company has a solid cash position of $100 million, providing financial stability.
• The CYPRESS study for ampreloxetine is progressing well, with enrollment expected to complete in the second half of 2024.
• The company is eligible for significant milestone payments from TRELEGY sales, potentially boosting future revenue.

Negatives

• The company reported a net loss of $11.7 million for the quarter, although this is an improvement from the previous year.
• The company is still operating at a loss, although the non-GAAP loss is significantly reduced.
• Share-based compensation expenses remain a significant cost, totaling $5.2 million for the quarter.

Risks

• The company's future profitability is subject to risks related to clinical trial outcomes, regulatory approvals, and market acceptance of its products.
• There is a risk that the company may not achieve the sales milestones for TRELEGY, impacting potential revenue.
• The company is dependent on third parties for the commercialization of YUPELRI and the development of ampreloxetine.
• The company's financial performance is subject to general economic and market conditions.

Future Outlook

The company expects to approach non-GAAP breakeven in the second half of 2024 and anticipates limited cash burn for the full year. They also expect to complete enrollment in the open-label portion of the CYPRESS study in the second half of 2024.

Management Comments

• Rick E Winningham, Chief Executive Officer, stated that the company delivered a solid quarter of YUPELRI hospital sales execution and is focused on YUPELRI growth and CYPRESS execution.
• Management is looking forward to sharing more about their progress and plans for ampreloxetine at a Key Opinion Leader-led virtual investor event scheduled for May 23rd.

Industry Context

The company's focus on respiratory and neurological treatments aligns with the growing demand for therapies in these areas. The increase in YUPELRI sales reflects a positive trend in the COPD market, while the development of ampreloxetine addresses an unmet need in the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy.

Comparison to Industry Standards

• Theravance Biopharma's 18% year-over-year growth in YUPELRI sales is a strong performance compared to the overall growth in the respiratory market.
• The company's focus on nebulized treatments for COPD positions them well in a niche market segment, with YUPELRI being the only once-daily nebulized LAMA.
• The development of ampreloxetine for MSA is a unique approach, as there are limited treatment options for this rare disease. The company's clinical trial design and focus on patient-reported outcomes are in line with industry best practices.
• Compared to companies like GSK, who market TRELEGY, Theravance is leveraging milestone payments and royalties to generate revenue, while focusing on their own pipeline.

Related Party Transactions

• The company has a co-promotion agreement with Viatris for YUPELRI, where Viatris leads commercialization and Theravance receives 35% of net profits.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and potential for future growth.
• Employees will be impacted by the company's strategic focus and operational changes.
• Patients will benefit from the development of new therapies for COPD and MSA.
• Viatris, as a key partner, will be impacted by the success of YUPELRI.

Next Steps

• The company will continue to enroll patients in the CYPRESS study for ampreloxetine.
• They will host a virtual KOL event on May 23, 2024, to discuss ampreloxetine.
• The company will continue to focus on growing YUPELRI sales in the US and expanding into China.
• They will work towards achieving TRELEGY sales milestones and receiving royalty payments.

Key Dates

Keywords

Theravance Biopharma, YUPELRI, Ampreloxetine, COPD, MSA, Neurogenic Orthostatic Hypotension, CYPRESS Study, Viatris, TRELEGY, Milestone Payments, Financial Results, Pharmaceuticals